Noor Riyadh 2023, the annual festival of light and art in Saudi Arabia, announces dates and themes for its third edition
- Noor Riyadh Festival returns for its third edition, which will feature over 120 artworks by more than 100 artists across five hubs in the capital of Saudi Arabia, from November 30 to December 16
- The festival features local and international artists and offers diverse workshops, thought-provoking seminars, and stimulating artistic discussions.
- The curatorial team of the Noor Riyadh 2023 festival is composed of Jérôme Sans as Lead Curator, Pedro Alonzo, Fahad Bin Naif and Alaa Tarabzouni as Curators.
- For the Noor Riyadh exhibition, which runs concurrently with the festival starting November 30, 2023, until March 2, 2024, Neville Wakefield will be Lead Curator and Maya Al Athel, Curator.
RIYADH, Saudi Arabia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Noor Riyadh, the Largest Light Art Festival in the World, will return for its third edition in Riyadh, with the festival running from November 30 to December 16, 2023, and the exhibition from November 30, 2023 to March 2, 2024.
The citywide festival will illuminate Riyadh with large-scale light art installations, building projections, performances, and more. Artworks will be displayed in public spaces across five hubs.
Curated by Jérôme Sans (Lead Curator), Pedro Alonzo, Alaa Tarabzouni, and Fahad Bin Naif (Curators), the festival’s theme is “The Bright Side of the Desert Moon” and will feature over 120 artworks by around 100 artists (more than 35 from Saudi Arabia) from more than 35 nationalities. Sans is the co-founder of Paris’ Palais de Tokyo, possessing an established career as curator of major biennials around the world and artistic director of prestigious institutions in Europe, Asia, and Latin America. On the other hand, Boston-based Alonzo is currently adjunct curator at Dallas Contemporary in Texas and specializes in shows that go beyond museum walls. Riyadh-based Tarabzouni and Bin Naif are both artists and curators, with individual practices that utilize their architectural backgrounds to bring unique perspectives on urbanism and the built environment.
The festival’s exhibition “Refracting Identities, Shared Futures” will be held at the JAX District. Neville Wakefield, formerly of MoMA PS1, Frieze Projects, and Desert X, returns to lead the curation of the show alongside Maya Al Athel, Curator, who served as artistic director of the festival in 2022.
Noor Riyadh 2023 will also feature over 500 community engagement programs for all visitors and families alike throughout the duration of the festival and the exhibition.
His Highness Prince Badr bin Farhan Al Saud, Minister of Culture, Board Member of the Royal Commission for Riyadh City, and Chairman of the Steering Committee for the Riyadh Art Program, said: “Under the guidance of His Royal Highness the Crown Prince and Prime Minister, our dedication to culture and the arts has opened doors for creative expression. The participation of renowned global light artists in Noor Riyadh echoes our united vision. As we approach our third edition, we look forward to continuing Riyadh Art’s mission to turn the city into a dazzling gallery without walls and to ensure that art is for everyone."
Developed with the aim of nurturing local talent and amplifying Saudi Arabia’s cultural economy, Noor Riyadh is part of Riyadh Art, one of the largest public art initiatives in the world. Riyadh Art aims to transform the Saudi capital into a “gallery without walls”, with more than 1,000 public art installations, to be spread out across the city through 10 programs and two annual events.
Across its editions, Noor Riyadh has created unique moments of joy across the city and provided millions of visitors the opportunity to appreciate world-class light artworks, and rediscover the city of Riyadh in a new light. In 2022, Noor Riyadh celebrated multiple achievements, including welcoming 2.8 million visitors to the festival and winning six Guinness World Records, one of which being the largest celebration of light art in the world.
Noor Riyadh 2023 press kit can be found here: https://drive.google.com/drive/folders/1QbBqglWTQGqKzG9FaJrpEn-p0LApRToE?usp=drive_link
For more information regarding Riyadh Art and Noor Riyadh contact:
Anastasia Lander at Pelham Communications email@example.com
Andrew Johnson at H+K Strategies firstname.lastname@example.org
Riyadh Art Media Center email@example.com
Notes to editors
About Noor Riyadh
Noor Riyadh is a citywide annual festival of light and art which launched in March 2021. Noor Riyadh includes a festival and world-class exhibition, along with a public program of activities for the community that includes educational workshops, talks, and performances. Noor Riyadh is the largest light art festival in the world.
Noor Riyadh combines the highest quality light artworks from leading international and Saudi artists, across the largest city footprint of any light art festival worldwide. Staged under Riyadh Art, the festival aims to nurture local talent and inspire youth to drive Saudi Arabia’s creative economy.
Noor Riyadh is presented by Riyadh Art and the Royal Commission for Riyadh City.
About Riyadh Art
Riyadh, the capital city of Saudi Arabia, is on a ten-year mission to become one of the world's most livable and competitive cities, a global city which is open for business and that welcomes the world. With a young and rapidly growing population of 7+ million residents, Riyadh is transforming into a vibrant and cosmopolitan global city.
Art and culture reflect the spirit of a city. That’s why the Riyadh Art project has been developed to turn the whole capital into a creative canvas - a gallery without walls - to enrich lives, ignite creative expression and kindle the creative economy. Riyadh Art is a demonstration of the open, accessible and creative transformation of the capital, where the exchange of ideas through creative expression, develops a deeper mutual understanding and respect.
The Riyadh Art project will have a positive impact on people, bringing every day moments of joy to residents and visitors alike, while instilling a greater sense of civic pride and creating a more beautiful city for everyone to enjoy. It will also spark the development of the new creative economy and have a positive effect in attracting new businesses to invest in the city.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0489d93e-7d01-4e18-9bd6-fd99c991c6c7To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote
Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release
Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla
Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release
29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the
Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel